Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK Dose Proportionality Study of OPL-002
NCT04451811Phase 1Completed
- Sponsor
- Oppilan Pharma
- Start
- Sep 2020
- Primary completion
- Feb 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of tamuzimod in ulcerative colitis (UC) (3 arms), sponsored by Oppilan Pharma. Primary endpoint: Area Under the Curve. Started Sep 2020; status: completed.
02
Drugs
tamuzimod
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT04451811.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04451811.